Opus Genetics
NASDAQ: IRDRaleigh, US · Founded 2021 · Delaware corporation · 46 employees on LinkedIn · 2 known investors
Find your way into Opus Genetics
946 people in our graph share verified history with the Opus Genetics team — schools, employers, funds. One of them is your warm intro.
Matt Cherianunlockedknows Nirav Jhaveri · together at Bank of America (overlapped)
×2knows the team · via Bank of America
×2knows the team · via Medpace
knows the team · via The Johns Hopkins University
knows the team · via University of Leicester
×3knows the team · via James Madison University
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.
Founders & leadership
Opus Genetics was founded in 2021 by Dr. Jean Bennett.
DJ
Dr. Jean BennettFounder
BH
Bernhard HoffmannExecutive
NJ
Nirav JhaveriinChief Financial Officer2024–2025Nirav Jhaveri has spent over 25 years in capital markets and corporate finance roles at public and venture-backed biopharma companies, with experience in IPO preparation, fundraising, and business operations. He has held finance leadership positions guiding organizations through capital strategy and growth.
AR
Amy RabourninHead of Financial Quality Assurance
GM
George MagrathinChief Executive OfficerGeorge Magrath is an ophthalmologist and CEO of Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases. He previously worked as an equity analyst covering biopharmaceutical companies, led drug development programs in respiratory, dermatology, and ophthalmology at Hovione, and served as CEO of Lexitas, where he oversaw organizational expansion and a strategic transaction.
BY
RG
Robert GagnonChief Financial Officer
JS
Joe SchachleinChief Operating OfficerJoe Schachle is Chief Operating Officer at Opus Genetics, a clinical-stage biopharmaceutical company developing genetic therapies for inherited retinal diseases. He has held executive roles across large pharmaceutical and biotech firms, overseeing commercial, corporate, and operational functions including sales, marketing, finance, and strategic planning in ophthalmology and other therapeutic areas.
AJ
Ash JayagopalinChief Scientific and Development OfficerAsh Jayagopal is Chief Scientific and Development Officer at Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company focused on genetic medicine for inherited retinal diseases. He previously led ophthalmology R&D at Roche, where he contributed to the development of VABYSMO® and guided multiple gene therapies and large molecules through clinical development stages.
ST
Sally TuckerinChief Medical OfficerSally Tucker holds a PhD in Ophthalmology and has led clinical trial operations and business development across pharmaceutical and medical device companies, including Top 30 pharma firms, with experience managing clinical research phases internationally and directing her own company.
ST
Sarah TullerinChief Regulatory OfficerSarah Tuller is Chief Regulatory Officer at Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases. She has a legal and chemistry background with extensive regulatory affairs experience across biologics and drugs at both large and small companies, including managing regulatory teams and overseeing US and global marketing authorizations.
CE
Chris ErnstinChief Technology OfficerChris Ernst is Chief Technology Officer at Opus Genetics, a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases. He brings expertise in quality assurance, regulatory affairs, and manufacturing oversight across biotechnology, CROs, and pharmaceutical companies, with specific experience in cell and gene therapy development and cGMP compliance.
Investors · 2
Reported raises · per SEC filings
Form D private placements$60.9M disclosed across 4 rounds · 2020–2024
▶$25.8MraisedNov 2024 · 11 investors · BiotechnologyRule 506(b)
▶$25.8MraisedNov 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Jean BennettDirector
- Dr. Benjamin YerxaDirector, Executive Officer
- Sean AinsworthDirector
- Bernhard HoffmannExecutive Officer
- Dr. Adrienne GravesDirector
- Richard RodgersDirector
- James ManusoDirector
- Nirav JhaveriExecutive Officer
- Ash JayagopalExecutive Officer
- Cam GallagherDirector
- Susan BentonDirector
- Amy RabournExecutive Officer
- Joseph SchachleExecutive Officer
- Dr. George MagrathDirector, Executive Officer
- Offering amount
- $25.8M
- Amount sold
- $25.8M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedJun 2023 · 5 investors · BiotechnologyRule 506(b)
▶$4.5MraisedJun 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JEAN BENNETTDirector
- RUSSELL KELLEYDirector
- BENJAMIN R. YERXAExecutive Officer, Director
- ADRIENNE GRAVESDirector
- Offering amount
- $20M
- Amount sold
- $4.5M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$9.5MraisedAug 2021 · 5 investors · Other Health CareRule 506(b)
▶$9.5MraisedAug 2021 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- BENJAMIN R. YERXAExecutive Officer, Director
- JEAN BENNETTDirector
- RUSSELL KELLEYExecutive Officer, Director
- Offering amount
- $19M
- Amount sold
- $9.5M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$21.1MraisedNov 2020 · 18 investors · BiotechnologyRule 506(b)
▶$21.1MraisedNov 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James S. ManusoDirector
- Mina SoochExecutive Officer, Director
- Alan R. MeyerDirector
- Sean AinsworthDirector
- Amy Zaremba RabournExecutive Officer
- Cam GallagherDirector
- Susan K. BentonDirector
- Richard J. RodgersDirector
- Bernhard HoffmannExecutive Officer
- Offering amount
- $21.1M
- Amount sold
- $21.1M
- Sales commissions
- $1.6M
- Placement agents
- Canaccord Genuity LLC, Cantor Fitzgerald & Co.
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Opus Genetics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Opus Genetics (Nasdaq: IRD) posts Q2 2026 loss, extends cash runway into 2029stocktitan.net · Aug 2026Frequently asked questions
- What does Opus Genetics do?
- Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.
- Who founded Opus Genetics?
- Opus Genetics was founded by Dr. Jean Bennett in 2021.
- Who are Opus Genetics's investors?
- Opus Genetics's investors include Michigan Capital Network, Oberland Capital.
- How much funding has Opus Genetics raised?
- Opus Genetics has disclosed $60.9M raised across 4 rounds.
- Where is Opus Genetics headquartered?
- Opus Genetics is headquartered in Raleigh, US.